Recent Updates
Recently added Catalysts
EVGN Positive Sentiment

Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs

Key Takeaway: Evogene Ltd. reported its Q3 and nine-month financial results for 2026, highlighting progress in its drug discovery program targeting acute graft-versus-host disease and AgPlenus' fungicide initiatives. The company generated novel small-molecule candidates with biological potency and promising activity against resistant fungal strains. Despite a decrease in revenues, Evogene continues to focus on building a proprietary asset pipeline.
Price reaction · baseline $0.35 (2026-11-18 close) · hit pre-market · clean, no other EVGN news in the window
day 0 close · peak
-10.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Advancement in drug discovery for aGVHD with promising candidates.
  • AgPlenus identified fungicides effective against resistant strains.
  • ChemPass AI technology shows potential in drug development.

Full Press Release Details

Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria
REHOVOT, Israel, Nov. 19, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a computational chemistry company leveraging proprietary AI-driven technologies to design and develop novel small molecules for the pharmaceutical and agricultural industries, today reported its financial results for the third quarter and first nine months of 2026, and provided an update on its business activities.
Ofer Haviv, Evogene's President and CEO, stated: "During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential. Alongside our collaborative discovery activities, we are advancing two internal development programs that represent an important component of our strategy to build a pipeline of proprietary assets fully owned and managed by Evogene.
The first one is our internal drug discovery program targeting acute graft-versus-host disease (aGVHD), a serious medical condition associated with significant unmet medical need. Within just several months, Using ChemPass AI™, we generated a series of novel, small-molecule candidates, that demonstrated biological potency, at nanomolar concentrations, as well as encouraging preliminary ADME and toxicology profiles. We are now focused on further optimizing these molecules, identifying the most promising candidates, and advancing the program toward IND-enabling studies. (For more information, please see our PR from 28, October 2026)
The second program, conducted through our subsidiary AgPlenus, focuses on discovering fungicides with new modes of action targeting Septoria tritici blotch, a major wheat disease for which resistance to existing fungicides is a growing challenge. Using ChemPass AI for Ag™, AgPlenus identified compounds that showed promising activity against fungicide-resistant Septoria strains. Selected compounds also reduced disease severity by up to 75%, compared to untreated controls, in plant tissue assays and demonstrating activity against additional fungal pathogens, indicating broader fungicidal potential. (For more information, please see our PR from 17, November 2026)
The progresses achieved across these initiatives demonstrates the ability of ChemPass AI™ and ChemPass AI for Ag™ to translate computational discovery into experimentally validated molecules exhibiting promising biological activity. More importantly, these programs reflect our strategic focus on converting technological capabilities into differentiated, proprietary product candidates offering meaningful commercial potential, ultimately creating long-term value for Evogene and its shareholders. "

Financial Results and Analysis

Cash Position

As of September 30, 2026, Evogene held consolidated cash, cash equivalents and short-term bank deposits of approximately $9.2 million. Consolidated cash usage during the third quarter of 2026 was approximately $2.4 million, including a Directors' and Officers' insurance payment of approximately $0.5 million, covering an 18-month period.

Revenues

Revenues for the nine months of 2026 totaled approximately $0.8 million, compared to approximately $3.2 million in the same period of 2025, representing a decrease of approximately $2.4 million. The decrease is mainly attributable to lower revenue recognized by Casterra, which in the first half of 2025 included significant seed sales of approximately $2.0 million. Revenues for the third quarter of 2026 were approximately $0.1 million compared to approximately $0.3 million in the third quarter of 2025, mainly due to the conclusion of the license and collaboration agreement with Bayer in May 2026.

Research and Development Expenses

Research and development expenses, net of non-refundable grants, for the nine months of 2026 were approximately $4.5 million, compared to approximately $4.6 million in the corresponding period of 2025, representing a decrease of approximately $0.1 million. For the third quarter of 2026, R&D expenses were approximately $1.5 million, an increase from $1.1 million in the same period of 2025. The increase was mainly attributable to the recognition of a non-refundable grant of approximately $0.2 million and an adjustment to liabilities in respect of government grants of approximately $0.1 million, both of which reduced R&D expenses in the third quarter of 2025, as well as the impact of fluctuations in the USD/NIS exchange rate, between the periods.

Sales and Marketing Expenses

Sales and marketing expenses for the nine months of 2026 were approximately $0.9 million, compared to approximately $1.1 million in the corresponding period of 2025. Sales and marketing expenses for the third quarter of 2026 were approximately $0.2 million, compared to approximately $0.4 million in the third quarter of 2025, primarily due to lower sales and marketing expenses at Casterra and AgPlenus.

General and Administrative Expenses

General and administrative expenses for the nine months ended September 30, 2026, decreased slightly to approximately $3.1 million, compared to approximately $3.2 million in the corresponding period of 2025. For the third quarter of 2026, general and administrative expenses were approximately $1.1 million, remaining relatively unchanged compared to the same period of 2025. The decrease in general and administrative expenses across Evogene and its subsidiaries was largely offset, mainly by transaction costs associated with the warrant inducement transaction and additional non-recurring legal expenses related to corporate governance and shareholders matters. These costs totaled approximately $0.4 million and $0.3 million during the nine-month and three-month periods ended September 30, 2026, respectively.

Financing Expenses (Income), Net

Financing expenses, net, for the nine months of 2026 were approximately $1.6 million, compared to financing income, net, of approximately $0.9 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction. As part of the February 2026 warrant inducement transaction, the Company recorded financing expenses of approximately $3.8 million during the first nine months of 2026. In addition, the Company recorded financing income of approximately $2.3 million related to the revaluation of warrants liability as of September 30, 2026. For the third quarter of 2026, financing income, net, was approximately $176 thousand, compared to approximately $79 thousand in the corresponding period of 2025, with no material change between the periods.

Loss from Discontinued Operations

Loss from discontinued operations, net, for the nine months of 2026 was approximately $0.5 million, compared to an income from discontinued operations, net, of approximately $4.0 million in the corresponding period of 2025. For the third quarter of 2026, the loss from discontinued operations was approximately $0.06 million, compared to income of approximately $7.6 million in the third quarter of the previous year. These amounts primarily reflect the financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag, to ICL in July 2025 and the licensing agreement with Lishan in February 2026, Lavie Bio's and Biomica's operating expense levels have decreased significantly. Biomica's operations were classified as discontinued operations beginning in the second quarter of 2026, and accordingly, the 2025 comparative figures have been reclassified to conform to the current period presentation. Lavie Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, had already been classified as discontinued operations in 2025.
Net loss for the nine months ended September 30, 2026, was approximately $10.5 million, compared to approximately $2.5 million in the corresponding period of 2025. The $8.0 million increase in net loss was primarily attributable to lower revenues, higher financing expenses, and income recognized in connection with the ICL transaction during the corresponding period of 2025. For the third quarter of 2026, net loss was approximately $2.9 million, compared to net income of approximately $5.2 million in the same period of 2025. The change was primarily attributable to income recognized in connection with the ICL transaction during the third quarter of 2025, as discussed above.

About Evogene Ltd.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.

About AgPlenus Ltd.

AgPlenus, a subsidiary of Evogene Ltd., is an AI-driven crop protection discovery company focused on developing effective and sustainable solutions to address the growing challenge of pesticide resistance. The company leverages ChemPass AI for Ag™, a technology platform licensed from Evogene, integrating predictive biology, artificial intelligence, and computational chemistry to discover novel crop-protection molecules. Through its target-based discovery approach, AgPlenus aims to improve discovery efficiency, reduce development risks, and advance differentiated crop-protection solutions with the potential to address unmet agricultural needs.
For more information, please visit www.agplenus.com

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses, among other things: its advancing its existing pharmaceutical and agricultural division programs toward subsequent stages of development; its potential, future revenue generation as its pharmaceutical programs progress through development and toward commercialization; its potential establishment of additional collaborations with leading biotechnology and pharmaceutical companies; its advancement of its internal high-value programs, including its internal drug discovery program under which proprietary molecules have the potential to serve as candidates for future preclinical development; its discovery program for new fungicides via AgPlenus; pursuit of strategic partnerships in agriculture; its continuing to strengthen its computational platform; and its ability to execute its strategy and create long-term shareholder value.
Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including: the aftermath of the recent wars between Israel and the United States, on the one hand, and Iran and its proxy terrorist groups, Hamas, Hezbollah, and, intermittently, the Houthis in Yemen, on the other hand, (and any destabilizations in Israel, neighboring territories or the Middle East region resulting from those wars; Evogene's and its subsidiaries' reliance on third parties to conduct certain activities, such as field-trials and pre-clinical studies, which could cause significant delays in the conduct of those activities; the potential impact of a change of control of Evogene's board of directors due to the actions of dissident shareholders; as well as those additional risk factors identified in Evogene's reports filed with the applicable securities authority. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Evogene's actual results to differ from those reflected in its forward-looking statements, please see "Item 3.D. Risk Factors" in Evogene's Annual Report on Form 20-F for the year ended December 31, 2025, and its subsequent reports filed with or furnished to the U.S. Securities and Exchange Commission and Israeli Securities Authority. You should not place undue reliance on any forward-looking statements included in this press release. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions, except to the extent required by applicable law.
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands
September 30, December 31,
2026 2025
Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 8,571 $ 12,956
Restricted cash 33 32
Short-term bank deposits 655 -
Trade receivables 232 317
Other receivables and prepaid expenses 1,181 1,565
Deferred expenses related to issuance of warrants - 551
Inventories 65 210
10,737 15,631
LONG-TERM ASSETS:
Long-term deposits and other receivables 5 571
Investment accounted for using the equity method - 43
Deferred expenses related to issuance of warrants - 1,165
Right-of-use-assets 1,446 1,824
Property, plant and equipment, net 446 812
1,897 4,415
TOTAL ASSETS $ 12,634 $ 20,046
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Trade payables $ 593 $ 639
Employees and payroll accruals 703 861
Lease liabilities 618 716
Liabilities in respect of government grants 142 56
Deferred revenues and other advances 21 17
Warrants and pre-funded warrants liability 496 706
Other payables 389 449
2,962 3,444
LONG-TERM LIABILITIES:
Lease liabilities 1,287 1,482
Liabilities in respect of government grants 3,082 3,073
Deferred revenues and other advances 60 72
4,429 4,627
TOTAL LIABILITIES $ 7,391 $ 8,071
CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION
U.S. dollars in thousands
SHAREHOLDERS' EQUITY:
Ordinary shares of NIS 0.2 par value: Authorized − 30,000,000 ordinary shares; Issued and outstanding – 18,052,405 ordinary shares on September 30, 2026 and 8,718,193 ordinary shares on December 31, 2025 1,103 488
Share premium and other capital reserves 288,212 281,986
Accumulated deficit (293,043) (282,556)
Equity attributable to equity holders of the Company (3,728) (82)
Non-controlling interests 8,971 12,057
TOTAL EQUITY 5,243 11,975
TOTAL LIABILITIES AND EQUITY $ 12,634 $ 20,046
CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS
U.S. dollars in thousands (except share and per share amounts)
Nine months ended September 30, Three months ended September 30, Year ended December 31,
2026 2025 (*) 2026 2025 (*) 2025 (*)
Unaudited Audited
Revenues $ 822 $ 3,189 $ 141 $ 312 $ 3,503
Cost of revenues:
Inventory impairment - - - - 2,180
Other cost of revenues 428 1,810 92 157 1,914
Total Cost of Revenues 428 1,810 92 157 4,094
Gross profit 394 1,379 49 155 (591)
Operating expenses:
Research and development, net 4,466 4,635 1,528 1,133 6,262
Sales and marketing 908 1,061 200 358 1,359
General and administrative 3,096 3,154 1,112 1,091 4,021
Other expenses (income) 293 (191) 191 - (205)
Total operating expenses, net 8,763 8,659 3,031 2,582 11,437
Operating loss (8,369) (7,280) (2,982) (2,427) (12,028)
Financing income 2,559 2,352 255 513 2,618
Financing expenses (4,124) (1,445) (79) (434) (1,841)
Financing income (expenses), net (1,565) 907 176 79 777
Share of loss from equity accounted investment ((43 (82) - (16) (39)
Loss before taxes on income (9,977) (6,455) (2,806) (2,364) (11,290)
Taxes on income (tax benefit) - 1 - - 1
Loss from continuing operations (9,977) (6,456) (2,806) (2,364) (11,291)
Income (loss) from discontinued operations, net (548) 3,983 (56) 7,561 3,464
Net income (loss) $ (10,525) $ (2,473) $ (2,862) $ 5,197 $ (7,827)
Attributable to:
Equity holders of the Company $ (10,487) $ (3,176) $ (2,849) $ 3,874 (8,485)
Non-controlling interests (38) 703 (13) 1,323 658
$ (10,525) $ (2,473) $ (2,862) $ 5,197 $ (7,827)
Basic and diluted loss per share from continuing operations, attributable to equity holders of the Company $ (0.75) $ (0.84) $ (0.17) $ (0.27) $ (1.41)
Basic and diluted loss per share from discontinued operations, attributable to equity holders of the Company $ (0.04) $ 0.42 $ (0.00) $ 0.71 $ 0.33
Weighted average number of shares used in computing basic and diluted loss per share 13,245,869 7,588,486 16,894,446 8,716,424 7,874,039
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
Nine months ended September 30, Three months ended September 30, Year ended December 31,
2026 2025 (*) 2026 2025 (*) 2025 (*)
Unaudited Audited
Cash flows from operating activities
Loss from continuing operations $ (9,977) $ (6,456) $ (2,806) $ (2,364) $ (11,291)
Adjustments to reconcile loss to net cash used in operating activities:
Adjustments to the profit or loss items:
Depreciation of property, plant and equipment and right-of-use-assets 501 748 167 241 971
Impairment of Property, Plant and Equipment 116 - - - -
Inventory impairment - - - - 2,180
Share-based compensation 80) 570 (13) 125 728
Remeasurement of Convertible SAFE - (371) - (26) (371)
Net financing expenses (income) (73) 21 (81) (135) (28)
Loss (gain) from sale of property, plant and equipment (17) (192) (3) 2 (205)
Revaluation of government grants 27 24 18 24 40
Amortization of deferred expenses related to issuance of warrants 1,716 989 - 333 1,323
Remeasurement of pre-funded warrants and warrants (2,271) (1,664) (163) (346) (1,781)
Expenses related to warrants inducement transaction 2,095 - - - -
Share of loss of an associate 43 82 - 15 39
Allowance for doubtful accounts 78 - 78 - -
Investment in sub-lease 194 - 194 - -
Taxes on income (tax benefit) - 1 - - (6)
2,489 208 197 233 2,890
Changes in asset and liability items:
Decrease in trade receivables 7 667 74 730 665
Decrease (increase) in other receivables and prepaid expenses (114) 870 (388) (417) 958
Decrease (increase) in inventories 145 (740) 28 (139) (1,019)
Increase (decrease) in trade payables 62 (195) 187 (31) (40)
Decrease in employees and payroll accruals (143) (335) (204) (226) (494)
Increase (decrease) in other payables 16 (343) 117 (45) (344)
Decrease in deferred revenues and other advances (8) (356) (5) (5) (361)
(35) (432) (191) (133) (635)
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
Nine months ended September 30, Three months ended September 30, Year ended December 31,
2026 2025 (*) 2026 2025 (*) 2025 (*)
Unaudited Audited
Cash received (paid) during the period for:
Interest received 246 221 46 45 338
Interest paid (104) (221) (20) (70) (256)
Taxes paid (5) (11) - - (11)
Net cash used in continuing operating activities (7,386) (6,691) (2,774) (2,289) (8,965)
Net cash provided by (used in) discontinued operations activities (287) (4,125) 13 (1,044) (4,537)
Net cash used in operating activities $ (7,673) $ (10,816) $ (2,761) $ (3,333) $ (13,502)
Cash flows from investing activities:
Purchase of property, plant and equipment $ (13( (129) (2) (7) $ (199)
Proceeds from sale of property, plant and equipment 115 10 3 10 78
Proceeds from finance sub-lease asset 17 29 - 12 52
Investment in bank deposits, net (655) (3,700) (655) (2,699) (1)
Net cash provided by (used in) continuing investing activities (536) (3,790) (654) (2,684) (70)
Net cash provided by (used in) discontinued investing activities 483 11,265 483 13,593 17,808
Net cash provided by (used in) investing activities $ 53) ( $ 7,475 $ (171) $ 10,909 $ 17,738
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.
CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
Nine months ended September 30, Three months ended September 30, Year ended December 31,
2026 2025 (*) 2026 2025 (*) 2025 (*)
Unaudited Audited
Cash flows from financing activities:
Proceeds from issuance of ordinary shares, net of issuance expenses 3,155 4,283 2,350 - 4,283
Proceeds from issuance of ordinary shares in warrant inducement transaction, net of issuance expenses 3,206 - - - -
Repayment of lease liability (334) (315) (121) (87) (423)
Dividend paid by subsidiary (2,672) - - - -
Repayment of convertible SAFE - (10,000) - (10,000) (10,000)
Proceeds from government grants 101 - - - -
Repayment of government grants (34) (122) (14) - (244)
Net cash provided by (used in) continuing financing activities 3,422 (6,154) 2,215 (10,087) (6,384)
Net cash used in discontinued financing activities (80) (192) (30) (249) (218)
Net cash provided by (used in) financing activities $ 3,342 $ (6,346) $ 2,185 $ (10,336) $ (6,602)
Exchange rate differences - cash and cash equivalent balances (1) 12 2 (13) 21
Decrease in cash and cash equivalents (4,385) (9,675) (745) (2,773) (2,345)
Cash and cash equivalents, beginning of the period 12,956 15,301 9,316 8,329 15,301
Cash and cash equivalents presented in assets held for sale - - - 70 -
Cash and cash equivalents, end of the period $ 8,571 $ 5,626 $ 8,571 $ 5,626 $ 12,956
Significant non-cash activities
Acquisition of property, plant and equipment $ - $ 2 $ - $ - $ 2
Right-of-use asset recognized with corresponding lease liability $ 33 $ 207 $- $ - $ 207
Exercise of pre-funded warrants $ - $ 389 $ - $ - $ 389
Derecognition of property, plant and equipment under a finance lease $ - $ 13 $ - $ - 13 $
(*) Reclassified to conform to the current period presentation, following the classification of certain operations as discontinued operations.

Frequently Asked Questions

What are Evogene's recent financial results?

Evogene reported revenues of approximately $0.8 million for the first nine months of 2026.

What is Evogene's focus in drug discovery?

Evogene is targeting acute graft-versus-host disease with novel small-molecule candidates.

How is AgPlenus contributing to Evogene's strategy?

AgPlenus is discovering fungicides effective against resistant strains of Septoria.

What technology does Evogene use for drug development?

Evogene leverages its ChemPass AI technology for drug discovery and development.

Last updated: Nov 19, 2026